Eton Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 4/4
Eton Pharmaceuticals CEO'su Sean Brynjelsen, Jun2017 tarihinde atandı, in görev süresi 9.17 yıldır. in toplam yıllık tazminatı $ 2.91M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.4% maaş ve 75.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.71% ine doğrudan sahiptir ve bu hisseler $ 63.58M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 8.9 yıldır.
Anahtar bilgiler
Sean Brynjelsen
İcra Kurulu Başkanı
US$2.9m
Toplam tazminat
| CEO maaş yüzdesi | 24.44% |
| CEO görev süresi | 9.2yrs |
| CEO sahipliği | 3.7% |
| Yönetim ortalama görev süresi | 2.1yrs |
| Yönetim Kurulu ortalama görev süresi | 8.9yrs |
Son yönetim güncellemeleri
Recent updates
Analiz Makalesi • Aug 19
Forecast: Analysts Think Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Business Prospects Have Improved Drastically
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Aug 14
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
Summary Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%. I rate ETON stock a Buy, supported by robust execution, scalable commercial strategy, and a 2-3 year target valuation above $2.5 billion despite current premium multiples. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 12
ETON: Ultra Rare Focus And New Guidance Will Drive Future Upside
Analysts have raised the fair value estimate for Eton Pharmaceuticals from $40 to $60. This change reflects updated models that factor in higher long term revenue assumptions for key products and recent price target increases across several research firms.
Anlatı Güncellemesi • Jul 28
ETON: Ultra Rare Disease Focus Will Drive Long Term Upside Potential
Analysts lifted the fair value estimate for Eton Pharmaceuticals to $62 from $57, reflecting updated price targets in the $60 to $62 range that factor in new product contributions, higher long term revenue assumptions for existing therapies, and more constructive views on its ultra rare disease portfolio. Analyst Commentary Recent Street research on Eton Pharmaceuticals points to a more constructive tone around the stock, with bullish analysts lifting price targets into the US$60 to US$62 range.Anlatı Güncellemesi • Jul 13
ETON: New Guidance And Drug Agreement Will Shape A Balanced Outlook
The analyst price target for Eton Pharmaceuticals has been raised from $52 to $57, with analysts citing updated fiscal 2026 revenue guidance and confidence in the company's growth strategy as key reasons for the change. What’s in the News for Eton Pharmaceuticals Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, sold about 126,685 shares for roughly US$4.77 million between July 2 and July 7, 2026, at weighted average prices near US$37 to US$38 per share, while retaining around 2.7 million shares (source: recent SEC filings summarized in news reports).
Anlatı Güncellemesi • Jun 29
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Eton Pharmaceuticals' analyst price targets have moved higher, with fair value estimates rising from about $39.33 to $45.67, as analysts point to updated revenue guidance and increased confidence in the company’s longer term growth plans. What’s in the News for Eton Pharmaceuticals Eton Pharmaceuticals was added to the S&P Pharmaceuticals Select Industry Index, reflecting its inclusion in a broader sector benchmark.Anlatı Güncellemesi • Jun 15
ETON: Higher 2026 Revenue Outlook Will Support Long Term Upside Potential
Analysts have raised their price target on Eton Pharmaceuticals to $57 from $52, citing the company's updated fiscal 2026 revenue guidance and their view that its long term growth goals remain achievable. Analyst Commentary Bullish analysts are pointing to Eton Pharmaceuticals' updated fiscal 2026 revenue guidance as a key support for their higher valuation frameworks.Anlatı Güncellemesi • Jun 01
ETON: Higher 2026 Guidance And New Rare Disease Assets Will Drive Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $57 from $35, citing higher fiscal 2026 revenue guidance, stronger profitability assumptions, and confidence in the company’s growth strategy as key reasons for the revised valuation. Analyst Commentary Recent research updates show a clear cluster of bullish analysts raising their fair value assumptions on Eton Pharmaceuticals, with several target bumps tied directly to the company’s latest revenue outlook and portfolio moves.Anlatı Güncellemesi • May 03
ETON: Single New Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Analysts have lifted their price targets on Eton Pharmaceuticals by up to $15, citing updated assumptions for revenue growth, profit margins, and future P/E that reflect the recent Hemangeol acquisition and its potential contribution to the business. Analyst Commentary Recent research updates around Eton Pharmaceuticals focus heavily on the Hemangeol acquisition and how it might reshape the company’s growth mix, earnings profile, and valuation assumptions.Anlatı Güncellemesi • Apr 18
ETON: Hemangioma Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Narrative Update on Eton Pharmaceuticals Analysts have raised their price targets on Eton Pharmaceuticals by up to $15, citing the Hemangeol acquisition, its existing FDA approval for infantile hemangioma, and the view that the deal could be accretive with commercialization planned to begin in May. Analyst Commentary Bullish analysts are generally positive on Eton Pharmaceuticals following the acquisition of the U.S. rights to Hemangeol, and several have raised their price targets in response.Anlatı Güncellemesi • Apr 04
ETON: Hemangioma Franchise Expansion Will Reshape Earnings Profile Through 2026
Analysts have raised the consolidated price target for Eton Pharmaceuticals from $30.00 to about $39.33, citing recent target increases from multiple firms and updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Eton Pharmaceuticals focuses heavily on the updated price targets, the Hemangeol acquisition, and how realistic current modeling assumptions appear against execution risks.Anlatı Güncellemesi • Mar 21
ETON: Upcoming Product Launches And New Guidance Will Reshape Earnings Profile
Analysts have raised the Eton Pharmaceuticals price target from $26 to $31, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that reflect their latest views on the company following recent research updates. Analyst Commentary Recent research updates highlight a mix of optimism about Eton Pharmaceuticals' growth opportunities and caution around how quickly those opportunities might translate into earnings and justify higher valuation multiples.Analiz Makalesi • Nov 14
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Share Price Matching Investor Opinion
With a price-to-sales (or "P/S") ratio of 6.4x Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) may be sending very bearish...Analiz Makalesi • Sep 24
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Jun 17
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 25% after a relatively good period...Yeni Anlatı • May 16
Increlex And Galzin Acquisitions Will Broaden Treatment Options
Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.Analiz Makalesi • May 16
Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
It's been a pretty great week for Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders, with its shares surging 14...Analiz Makalesi • May 02
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders are no doubt pleased to see that the share price has bounced...Analiz Makalesi • Feb 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...Analiz Makalesi • Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...Analiz Makalesi • Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
The Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) share price has done very well over the last month, posting an excellent...Analiz Makalesi • Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a really impressive month, gaining 40% after a shaky period...Analiz Makalesi • Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Market forces rained on the parade of Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders today, when the covering...Analiz Makalesi • Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) earnings announcement last week was disappointing for investors, despite...Analiz Makalesi • Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 26% after a relatively good period...Analiz Makalesi • Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$13m |
| Mar 31 2026 | n/a | n/a | -US$1m |
| Dec 31 2025 | US$3m | US$712k | -US$5m |
| Sep 30 2025 | n/a | n/a | -US$7m |
| Jun 30 2025 | n/a | n/a | -US$4m |
| Mar 31 2025 | n/a | n/a | -US$5m |
| Dec 31 2024 | US$2m | US$616k | -US$4m |
| Sep 30 2024 | n/a | n/a | -US$5m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | US$913k |
| Dec 31 2023 | US$2m | US$592k | -US$936k |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$234k |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$2m | US$570k | -US$9m |
| Sep 30 2022 | n/a | n/a | -US$9m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$12m |
| Dec 31 2021 | US$2m | US$542k | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$2m | US$476k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$21m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$2m | US$410k | -US$18m |
Tazminat ve Piyasa: Sean 'nin toplam tazminatı ($USD 2.91M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.19M ).
Tazminat ve Kazançlar: Sean 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Sean Brynjelsen (54 yo)
9.2yrs
Görev süresi
US$2,914,489
Tazminat
Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 9.2yrs | US$2.91m | 3.71% $ 63.6m | |
| Chief Business Officer | 3.4yrs | US$1.39m | 0.13% $ 2.2m | |
| Consultant | less than a year | US$1.40m | 0.056% $ 956.0k | |
| Chief Commercial Officer | 1.7yrs | US$575.29k | 0.0010% $ 17.3k | |
| Chief Financial Officer & Secretary | less than a year | Veri yok | Veri yok | |
| Chief Operating Officer | 2.6yrs | Veri yok | Veri yok | |
| Senior Vice President of Sales Operations | no data | Veri yok | Veri yok |
2.1yrs
Ortalama Görev Süresi
49yo
Ortalama Yaş
Deneyimli Yönetim: ETON 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 9.2yrs | US$2.91m | 3.71% $ 63.6m | |
| Independent Director | 8.9yrs | US$277.84k | 0.21% $ 3.6m | |
| Independent Director | 9.2yrs | US$275.14k | 0.24% $ 4.1m | |
| Independent Chairman | 8.9yrs | US$318.05k | 0.78% $ 13.4m | |
| Independent Director | 5.4yrs | US$267.03k | 0% $ 0 |
8.9yrs
Ortalama Görev Süresi
68yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ETON 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.9 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/21 09:30 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Eton Pharmaceuticals, Inc. 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Gary Nachman | Canaccord Genuity |